Skip to main content

Table 3 Association with relapse in the study group for the G2I and for various clinicopathological parameters

From: An array CGH based genomic instability index (G2I) is predictive of clinical outcome in breast cancer and reveals a subset of tumors without lymph node involvement but with poor prognosis

  Univariate analysis Multivariate analysis
Clinicopathological parameters All(a) n(%) No Relapse n(%) Relapse n(%) OR [CI 95%] p OR [CI 95%] p
G2I (b)        
Class 1 19 (14) 18 (20) 1 (2,2) 0,16[0,2-1,2] 0,08 0,24[0.03-2] 0.19
Class2 88 (65) 65 (72,2) 23 (51,1) 1   1  
Class3 28 (21) 7 (7,8) 21 (46,7) 8,5[3 ,2-22,6] <0,001 11.9[4.2-34.1] <0.001
SBR Grade (c)       rejected  
1 25 (18) 21 (23,3) 4 (8,9) 1    
2 71 (53) 46 (51,1) 25 (55,6) 2,9[0,9-9,2] 0,08   
3 39 (29) 23 (25,6) 16 (35,6) 3,7[1,05-12,7] 0,04   
Histological size       rejected  
≤ 20 mm. 90 (67) 67 (74,4) 23 (51,1) 1    
> 20 mm. 45 (33) 23 (25,6) 22 (48,9) 2,8[1, 3–5, 9] 0,008   
HR status (d)        
HR- 19 (14) 12 (13,3) 7 (15,6) 1,19[0 ,44- 0,72   
HR+ 116 (86) 78 (86,7) 38 (84,4) 3,3]    
NPI (e)        
1 + 2 30 (22) 24 (26,7) 6 (13,3) 1   1  
3 85 (63) 58 (64,4) 27 (60) 1,8[0,7-5,1] 0,23 1.38[0.4-4.4] 0.6
4 20 (15) 8 (8,9) 12 (26,7) 6[1,7-21,3] 0,006 7.2[1.8-29.3 0.006
TP53 alteration        
no 115 (85) 73 (81,1) 31 (68,9) 1    
yes 20 (15) 17 (18,9) 14 (31,1) 1,9[0,9-4,4] 0,11   
mib1 (f)       rejected  
<20% 93 (69) 67 (74,4) 26 (57,8) 1    
≥20% 42 (31) 23 (25,6) 19 (42,2) 2,1[1–4,5] 0,05   
IHC intrinsic class (g)
LA 83 (62) 59 (67) 24 (53,3) 1    
LB + Her2+ Basal 50 (38) 29 (33) 21 (37,6) 1,8[0,85-3,7] 0,12   
nd 2 2      
  1. (a) n: Number of tumors; % in parentheses; (b) G2I: Three classes of genomics instability index as defined here; (c) SBR: Scarff, Bloom and Richardson grade; (d) HR: Hormonal Receptor; HR-: negative hormonal receptor status evaluated by immunohistochemistry (IHC) with a threshold of 10% of tumors cells; (e) NPI: Nottingham Prognostic Index, 1 + 2: good or excellent, 3: moderate, 4: poor; (f) immunohistochemistry expression of mib1; (g) immunohistochemical intrinsic class: LA: Luminal A for HR+-tumors with mib1 expression in less than 20% of tumor cells, LB: Luminal B for HR+-tumors with mib1 expression in at least 20% of tumor cells or with Her2 score of 3, Her2: Her2-enriched tumors for HR- and Her2+-tumors, Basal for HR- and Her2--tumors that express at least one of the following protein in more than 10% of tumor cells: egfr, ck5/6, or vimentin;